Active Vascular Endothelial Growth Factor Receptor 2 (VEGFR2)
CD309; FLK1; VEGFR; KDR; A Type III Receptor Tyrosine Kinase; Kinase Insert Domain Receptor; Kinase Insert Domain Receptor; Fetal Liver Kinase-1
- 物种Homo sapiens (Human，人) 相同的名称，不同的物种。
- 缓冲液成份磷酸盐缓冲液（pH7.4，含有 0.01% SKL, 1mM DTT, 5% Trehalose和Proclin300.）
- 纯度> 97%
- 应用Cell culture; Activity Assays.
- 下载 英文说明书 中文说明书
- 规格 10µg50µg 200µg 1mg 5mg
- 价格 ¥ 1296 ¥ 3240 ¥ 6480 ¥ 19440 ¥ 48600
- Figure. Gene Sequencing (Extract)
- Figure. SDS-PAGE
- 通过ISO 9001、ISO 13485质量体系认证
Figure. Cell proliferation of ECV-304 cells inhibit by VEGFR2.
Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) also known as kinase insert domain receptor acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. VEGFR2 functions as the primary mediator of vascular endothelial growth factor activation in endothelial cells. Regulation of VEGFR-2 expression appears critical in mitogenesis, differentiation, and angiogenesis. To test the effect on inhibit the VEGF-dependent proliferation of endothelium cells, ECV-304 cells were seeded into triplicate wells of 96-well plates at a density of 5,000 cells/well and allowed to attach, replaced with serum-free overnight, then the medium was replaced with 2% serum standard DMEM including 1μg/mL Vascular Endothelial Growth Factor C (VEGFC) and various concentrations of recombinant human VEGFR2. After incubated for 96h, cells were observed by inverted microscope and cell proliferation was measured by Cell Counting Kit-8 (CCK-8). Briefly, 10µL of CCK-8 solution was added to each well of the plate, then the absorbance at 450nm was measured using a microplate reader after incubating the plate for 1-4 hours at 37℃. Proliferation of ECV-304 cells after incubation with VEGFR2 for 96h observed by inverted microscope was shown in Figure 1. Cell viability was assessed by CCK-8 (Cell Counting Kit-8) assay after incubation with recombinant VEGFR2 for 96h. The result was shown in Figure 2. It was obvious that VEGFR2 significantly inhibit cell viability of ECV-304.
(A) ECV-304 cells cultured in DMEM, stimulated with 10ng/mL VEGFR2 for 96h;
(B) Unstimulated ECV-304 cells cultured in DMEM for 96h.
Figure. VEGFR2 inhibit VEGF-dependent proliferation of ECV-304 cells.
Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
|编号||适用物种：Homo sapiens (Human，人)||应用(仅供研究使用，不用于临床诊断！)|
|APB367Hu61||血管内皮生长因子受体2(VEGFR2)活性蛋白||Cell culture; Activity Assays.|
|EPB367Hu61||血管内皮生长因子受体2(VEGFR2)真核蛋白||Positive Control; Immunogen; SDS-PAGE; WB.|
|APB367Hu01||血管内皮生长因子受体2(VEGFR2)活性蛋白||Cell culture; Activity Assays.|
|RPB367Hu01||血管内皮生长因子受体2(VEGFR2)重组蛋白||Positive Control; Immunogen; SDS-PAGE; WB.|
|PAB367Hu01||血管内皮生长因子受体2(VEGFR2)多克隆抗体||WB; IHC; ICC; IP.|
|LAB367Hu81||血管内皮生长因子受体2(VEGFR2)多克隆抗体(异硫氰酸荧光素标记)||WB; IHC; ICC; IF.|
|LAB367Hu71||血管内皮生长因子受体2(VEGFR2)多克隆抗体(生物素标记)||WB; IHC; ICC.|
|MAB367Hu22||血管内皮生长因子受体2(VEGFR2)单克隆抗体||WB; IHC; ICC; IP.|
|MAB367Hu21||血管内皮生长因子受体2(VEGFR2)单克隆抗体||WB; IHC; ICC; IP.|
|HEB367Hu||血管内皮生长因子受体2(VEGFR2)检测试剂盒(酶联免疫吸附试验法,高敏型)||Enzyme-linked immunosorbent assay for Antigen Detection.|
|SEB367Hu||血管内皮生长因子受体2(VEGFR2)检测试剂盒(酶联免疫吸附试验法)||Enzyme-linked immunosorbent assay for Antigen Detection.|
|APMIS||Peritumoral brain edema in angiomatous supratentorial meningiomas: an investigation of the vascular endothelial growth factor A pathway [PubMed: 23398358]|
|Acta Biomater||Antioxidant and bone repair properties of quercetin-functionalized hydroxyapatite: an in vitro osteoblast-osteoclast-endothelial cell co-culture study [PubMed: 26689470]|
|Acta Biomaterialia||Antioxidant and bone repair properties of quercetin-functionalized hydroxyapatite: An in vitro osteoblast–osteoclast–endothelial cell co-culture study [Pubmed:26689470]|
|Journal of Cellular Physiology||A Human 3D In Vitro Model to Assess the Relationship Between Osteoporosis and Disseminationto Bone of Breast Cancer Tumor Cells. [pubmed:27925188]|
|Regenerative Biomaterials||The directional migration and differentiation of mesenchymal stem cells toward vascular endothelial cells stimulated by biphasic calcium phosphate ceramic [10.1093/rb/rbx028]|
|International Journal of Immunopathology and Pharmacology||VEGF-R2 and TNF-R1 expression and cytokine production by samples of mammary adenocarcinomas and correlations with histopathological parameters of these … [Pubmed:29985074]|